Diana Boraschi
Diana Boraschi
Verified email at ibbc.cnr.it
Cited by
Cited by
From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation
P Italiani, D Boraschi
Frontiers in immunology 5, 514, 2014
Regulation of the macrophage content of neoplasms by chemoattractants
B Bottazzi, N Polentarutti, R Acero, A Balsari, D Boraschi, P Ghezzi, ...
Science 220 (4593), 210-212, 1983
IL-37: a new anti-inflammatory cytokine of the IL-1 family
D Boraschi, D Lucchesi, S Hainzl, M Leitner, E Maier, D Mangelberger, ...
European cytokine network 22 (3), 127-147, 2011
IL-1 family nomenclature
C Dinarello, W Arend, J Sims, D Smith, H Blumberg, L O'Neill, ...
Nature immunology 11 (11), 973-973, 2010
Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice
R Giavazzi, A Garofalo, MR Bani, M Abbate, P Ghezzi, D Boraschi, ...
Cancer research 50 (15), 4771-4775, 1990
IL-18 in autoimmunity
D Boraschi, CA Dinarello
European cytokine network 17 (4), 224-252, 2006
The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness
D Lang, J Knop, H Wesche, U Raffetseder, R Kurrle, D Boraschi, ...
The Journal of Immunology 161 (12), 6871-6877, 1998
Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles
M Lucarelli, AM Gatti, G Savarino, P Quattroni, L Martinelli, E Monari, ...
European cytokine network 15 (4), 339-346, 2004
The interleukin-1 receptor family
D Boraschi, A Tagliabue
Seminars in immunology 25 (6), 394-407, 2013
Human peritoneal mesothelial cells produce many cytokines (granulocyte colony-stimulating factor [CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6á…
L Lanfrancone, D Boraschi, P Ghiara, B Falini, F Grignani, G Peri, ...
Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production.
D Boraschi, S Censini, A Tagliabue
The Journal of Immunology 133 (2), 764-768, 1984
Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions
TJ Anchordoquy, D Barenholz, Y, Boraschi, etal.
ACS Nano 11, 12-18, 2017
A short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity
G Antoni, R Presentini, F Perin, A Tagliabue, P Ghiara, S Censini, ...
J Immunol 137 (10), 3201-3204, 1986
Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects
GJ Oostingh, E Casals, P Italiani, R Colognato, R Stritzinger, J Ponti, ...
Particle and fibre toxicology 8 (1), 1-21, 2011
Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table
O Parolini, F Alviano, I Bergwerf, D Boraschi, C De Bari, P De Waele, ...
Stem cells and development 19 (2), 143-154, 2010
The interleukin‐1 receptor family
D Boraschi, A Tagliabue
Vitamins & Hormones 74, 229-254, 2006
Antibody-dependent cell-mediated antibacterial activity of intestinal lymphocytes with secretory IgA
A Tagliabue, L Nencioni, L Villa, DF Keren, GH Lowell, D Boraschi
Nature 306 (5939), 184-186, 1983
Concern-driven integrated approaches to nanomaterial testing and assessment–report of the NanoSafety Cluster Working Group 10
AG Oomen, PMJ Bos, TF Fernandes, K Hund-Rinke, D Boraschi, ...
Nanotoxicology 8 (3), 334-348, 2014
Morphological characterization of a cell population responsible for natural killer activity.
W Luini, D Boraschi, S Alberti, A Aleotti, A Tagliabue
Immunology 43 (4), 663, 1981
Natural and antibody-dependent cell-mediated activity against Salmonella typhimurium by peripheral and intestinal lymphoid cells in mice.
L Nencioni, L Villa, D Boraschi, B Berti, A Tagliabue
The Journal of Immunology 130 (2), 903-907, 1983
The system can't perform the operation now. Try again later.
Articles 1–20